Last reviewed · How we verify

NCT06089109

Creating VIP Corps to Reduce Maternal Deaths

Recruiting now NA Last updated 7 October 2025
What this trial tests

NA trial testing The Big 3 in Maternal Morbidity and Mortality in 2,800 participants. Currently enrolling.

Timeline
25 September 2023
Primary endpoint
29 September 2026
29 September 2027

Quick facts

Lead sponsorAnn Coker
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment2,800
Start date25 September 2023
Primary completion29 September 2026
Estimated completion29 September 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ann Coker

Who can join

Adults 18 to 30, any sex, with Maternal Morbidity and Mortality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to create and rigorously evaluate a violence intervention and prevention corps (VIP Corps) training using a randomized controlled trial among undergraduate and professional students; and to develop a novel maternal injury surveillance system (MISS) to complement an existing maternal violent death registry in Kentucky.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ann Coker trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06089109.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing